ArticleDiseases of the esophagus : official journal of the International Society for Diseases of the Esophagus2026
pHoenix score discriminative ability in suspected gastroesophageal reflux disease: a high-volume single-center external validation.
Article in Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Does the pHoenix score reduce the inconclusive GERD diagnosis: a net reclassification index analysis.Therapeutic advances in gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pHoenix score was recently developed to reduce the proportion of inconclusive diagnoses associated with using total acid exposure time (AET) alone. The aim of this study was to compare the discriminative performance of the pHoenix score to total AET and DeMeester score (DMS) in patients undergoing 24-hour transnasal pH-monitoring (24-h pH). This cross-sectional study included consecutive patients (2017-2024) undergoing 24-h pH for suspected gastroesophageal reflux disease. Exclusions criteria were prior foregut/bariatric procedures, outflow obstruction disorders and inadequate pH-studies (<18 hours). The pHoenix score calculation was (%upright AET × 0.991) + (% supine AET × 1.286), with thresholds: <7.06 (normal), 7.06-8.45 (borderline), >8.45 (pathological). Total AET thresholds were: <4% (normal), 4-6% (borderline), and >6% (pathological). The DMS (pathological if >14.72) was the reference standard. Of 500 patients (50% females, median age 51 years, median BMI 24.65 kg/m2), 213 (43%) had pathological DMS. The pHoenix score and total AET identified a similar proportion of normal cases (54% vs. 56.2%, P > 0.99), but different pathological (40.4% vs. 30%, P < 0.01) and borderline diagnoses (5.6% vs. 13.8%, P < 0.01; with a 59% reduction with the pHoenix score). The pHoenix model showed strong performance (pseudo R2:0.877; Akaike information criterion = 83.57). Sensitivity/specificity were high at both 7.06 (99.1%/93.4%) and 8.45 (93.9%/99.3%) cutoffs. The AUC was 0.995 (95% CI: 0.987-1) for the pHoenix score, and 0.992 (95% CI: 0.987-0.997) for total AET. The pHoenix score, while maintaining a high diagnostic accuracy, offers a refined classification of acid exposure weighting supine/upright AET, thus reducing borderline diagnoses and potential need for further testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.